Davenport & Co’s Cognition Therapeutics CGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding CGTX
C
CM
Davenport & Co's CGTX Position: Q3 2026 in Review
Davenport & Co reduced its Cognition Therapeutics (CGTX) stake by 0.26% in Q3 2026, selling an estimated $11.2K and leaving 4,248,410 shares worth $4.08M. The position accounts for 0.02% of the portfolio, ranked #420.
Davenport & Co first reported a position in CGTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $4.9M in Q2 2026. 77 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.
- Davenport & Co held 4,248,410 shares of Cognition Therapeutics worth $4.08M as of Q3 2026.
- Davenport & Co sold 11,101 Cognition Therapeutics shares in Q3 2026, an estimated $11.2K.
- Cognition Therapeutics made up 0.02% of Davenport & Co's portfolio in Q3 2026, its #420 holding.
- Davenport & Co first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Davenport & Co's Cognition Therapeutics position peaked at $4.9M in Q2 2026.
- 77 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.
Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.